Your dog might live longer now
A biotech company called Loyal has developed a drug that slows aging in dogs by targeting the IGF-1 hormone, which has received acceptance from the FDA — marking the first time a regulator has acknowledged aging itself as treatable. The drug is designed for large dog breeds and could be available by 2027. The creator draws a parallel to human biology, suggesting this could eventually pave the way for human anti-aging treatments.
Summary
The transcript covers a major breakthrough in veterinary and biotech science: a San Francisco-based company called Loyal has developed a drug that does not treat a disease but instead slows the aging process itself in dogs. This is notable because it marks the first time the US drug regulator (the FDA) has accepted a drug with this specific purpose — targeting aging rather than a specific illness.
The science behind the drug centers on IGF-1, a growth hormone. The transcript explains that large dog breeds like Great Danes have up to 28 times more IGF-1 than small breeds like Chihuahuas, which is why large dogs grow bigger but live significantly shorter lives (7–10 years vs. 14–16 years). Loyal's drug works by reducing IGF-1 levels in adult dogs. It comes in two forms: an injection every 3 to 6 months for large breeds, and a daily pill for older dogs. The drug has been tested on over 1,300 dogs, and the first prescriptions could be written as early as 2027.
The presenter emphasizes a broader implication that is not widely discussed: for the first time in history, a regulatory body has formally recognized aging as something that can be pharmacologically treated. The presenter also notes that IGF-1 is not unique to dogs — it exists in humans too — suggesting that this veterinary breakthrough could be a precursor to human anti-aging medicine. The video ends with a call to action to join the presenter's WhatsApp community.
Key Insights
- The speaker explains that large dog breeds have up to 28 times more IGF-1 than small breeds, which causes faster growth but significantly shorter lifespans — nearly half that of smaller dogs like Chihuahuas.
- The speaker claims that for the first time in history, a drug regulator has formally accepted that aging itself — not a disease caused by aging — can be treated as a medical target.
- Loyal's drug works by lowering IGF-1 in adult dogs and comes in two forms: an injection every 3 to 6 months for large breeds, and a daily pill for older dogs at home.
- The speaker states the drug has been tested on over 1,300 dogs and the first prescription could be written as early as 2027, after which it could become as routine as vaccines for large breeds.
- The speaker argues that because the same IGF-1 hormone runs through every human body, dogs could be the first patients of anti-aging treatment, with humans potentially being next.
Topics
Transcript
[0:00] Your dog could now live long enough to see your kids grow up. One injection just made that possible. Welcome to day 33 of future tech updates. A biotech company in San Francisco just got America's drug regulator to accept something that has never been accepted before. A drug that does not cure a disease. It slows down aging itself. The catch, it is only for dogs. Here is the science and it is genuinely fascinating. A great Dane lives around 7 to 10 years. A Chihuahua lives 14 to 16. Same species, almost double the lifespan. Nobody ever questioned why. The answer [0:31] is one hormone called IGF-1. Big dogs have up to 28 times more of it…
Full transcript available for MurmurCast members
Sign Up to AccessMore from Vaibhav Sisinty
This New AI Agent Turns You Into a One-Person Company
The video showcases Axion Work, an AI agent platform by Alibaba that runs locally on your computer, through two real-world business tests: generating a market strategy for an Indian coffee brand (Drinkle/Bonhomie) and building a live Shopify dropshipping store from scratch. The creator argues this tool effectively replaces multiple business team roles — strategist, researcher, designer, and ops — for solo founders and small teams.
Why I Cancelled My Claude Code Subscription🔥
A short-form video tutorial explains how to replace Claude Code's Anthropic backend with a locally-run Qwen model via Ollama, eliminating API costs and rate limits. The presenter outlines three steps to redirect Claude Code to a local server. The video ends with a call-to-action for a setup link, WhatsApp community, and daily follow content.
Stop Using ChatGPT. Google Just Changed Everything🤯
The video introduces Gemini Spark, a Google product announced at IO 2026, which runs on dedicated Google servers rather than user devices. Unlike conventional AI tools, it continues working autonomously even when all user devices are off, learning user habits and completing tasks overnight. The presenter positions it as a paradigm shift from smart chatbots to persistent personal AI employees.
AI Just Took Over the Most Sensitive Room in Medicine🤯
A company called Conceivable Life Sciences has developed an AI-guided robotic system that autonomously performs key IVF steps, including sperm selection, egg positioning, and insemination. This technology could address the global shortage of skilled embryologists and reduce costs and wait times. While still early-stage and regulated, it marks a significant shift in AI moving from data analysis to hands-on medical procedures.
Claude Code vs. OpenCode: Which Agent is Better for 2026?🤯
A short-form video promotes OpenCode, a free open-source terminal-based alternative to Claude Code. The creator demonstrates a quick installation process and claims it handles the same tasks as Claude Code at no cost. The video ends with a call to action for links and a WhatsApp community.